Patients’ response to β-blockers in dependence of variations in the β1-adrenoceptor
Data are an overview of candidate gene studies investigating ≥100 individuals.
| Parameter (β-Blocker) | Cohort | Number of Subjects | Population Origin | Variation Effect | Reference |
|---|---|---|---|---|---|
| c.145A>G (p.Ser49Gly) | |||||
| Improvement in LVEF (carvedilol) | CHF | 135 | Australian | Ser = Gly | Chen et al. (2007) |
| 1-yr survival (not detailed) | CABG | 185 | German | Ser = Gly | Frey et al. (2011) |
| Improvement of LVEF (carvedilol or bisoprolol) | CHF | 199 | French | Ser = Gly | de Groote et al. (2005) |
| SBP/DBP response (atenolol) | HT | 267 | Italian | Ser = Gly | Filigheddu et al. (2004) |
| 5-yr survival (not detailed) | DCM | 375 (492 controls) | Swedish | Ser < Gly carriers | Magnusson et al. (2005) |
| 2.8-yr survival (carvedilol or metoprolol) | CHF | 637 | American | Ser = Gly | Sehnert et al. (2008) |
| c.1165C>G (p.Arg389Gly) | |||||
| Improvement in LVEF (carvedilol) | CHF | 135 | Australian | Arg > Gly carriers | Chen et al. (2007) |
| BP and HR response (bisoprolol/atenolol) | HT | 147 | British | Arg = Gly | O’Shaughnessy et al. (2000) |
| HR reduction (atenolol) | 164 | American | Arg > Gly | Kurnik et al. (2008) | |
| BP and HR response (metoprolol) | CHF | 165 | Chinese | Arg > Gly | Luo et al. (2007) |
| Improvement of LVEF (carvedilol) | CHF | 183 | Italian | Arg = Gly | Metra et al. (2010) |
| 1-yr survival (not detailed) | CABG | 185 | German | Arg = Gly | Frey et al. (2011) |
| Improvement of LVEF (carvedilol or bisoprolol) | CHF | 199 | French | Arg = Gly | de Groote et al. (2005) |
| BP response (bisoprolol) | HT | 233 | Finnish | Arg = Gly | Suonsyrjä et al. (2010) |
| Improvement of LVEF (carvedilol) | CHF | 224 | American | Arg carriers > Gly | Mialet Perez et al. (2003) |
| SBP/DBP response (atenolol) | HT | 255 | Italian | Arg = Gly | Filigheddu et al. (2004) |
| 5-yr survival (not detailed) | DCM | 375 (492 controls) | Swedish | Arg = Gly | Magnusson et al. (2005) |
| Heart rate response (bisoprolol/carvedilol) | CHF | 421 | Caucasian | Arg = Gly | Rau et al. (2012) |
| HR reduction, survival and adverse effects (metoprolol CR/XL) (MERIT-HF) | CHF | 600 | British and Dutch | Arg = Gly | White et al. (2003) |
| 2.8-yr survival (carvedilol or metoprolol) | CHF | 637 | American | Arg = Gly | Sehnert et al. (2008) |
| 3.5-yr survival (carvedilol or metoprolol) | CHF | 859 | American | Arg = Gly | Cresci et al. (2009) |
| 5-yr survival (bucindolol, BEST study) | CHF | 1040 | American | Arg > Gly carriers | Liggett et al. (2006) |
| Risk of cardiac event (bucindolol, BEST substudy) | CHF | 1040 | American | Arg > Gly | O’Connor et al. (2012) |
| Prevention of new-onset AF (bucindolol, BEST substudy) | HFREF | 1040 | American | Arg > Gly | Aleong et al. (2013) |
| Treatment response (atenolol) | CAD | 2973 | American | Arg > Gly | Pacanowski et al. (2008a) |
AF, atrial fibrillation; BEST, β-Blocker Evaluation of Survival Trial; BP, blood pressure; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, chronic heart failure; CR/XL, controlled release/extended release; DBP, diastolic blood pressure; DCM, dilated cardiomyopathy; HFREF, heart failure with reduced left ventricular ejection fraction; HR, heart rate; HT, hypertensive; LVEF, left ventricular ejection fraction; MERIT-HF, Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure; SBP, systolic blood pressure.